IMMUNEONCO-B (01541) subsidiary Yiming Kaier Biopharmaceutical Technology (Shanghai) has secured an investment of 50 million yuan.

IMMUNEONCO-B (01541) announced that on August 6, 2026, our company, Yiming Kail Bio-Pharmaceutical Technology (Shanghai) Co., Ltd. (the target company, a non-wholly-owned subsidiary of our company), Jiaxing Zhangke Lingyi Biotechnology Start-up Investment Partnership (Limited Partnership) (Lingyi Biotechnology), Suzhou New Realm Chuangyuan Enterprise Management Partnership (Limited Partnership) (New Realm Chuangyuan), and Mr. Wang Xueyan (Mr. Wang, collectively referred to as "Investors" with Lingyi Biotechnology and New Realm Chuangyuan) entered into a capital increase agreement. According to the capital increase agreement, the investors agree to contribute a total consideration of RMB 50 million to subscribe for a total of RMB 465,000 of the enlarged registered capital, accounting for approximately 15.83% of the target company's enlarged equity. Concurrently with the capital increase, in accordance with the agreement between our company and the target company, the target company will convert RMB 15.86 million of the unpaid principal and accrued interest owed to our company under existing loans into RMB 147,500 of the target company's enlarged registered capital at the subscription price per share applicable to the investors as stipulated in the capital increase agreement. Our company is a clinical-stage biotechnology company dedicated to developing tumor immunotherapy. The target company is an innovative drug development company focused on creating innovative drugs for metabolic diseases and rare diseases. By introducing external professional investors, this capital increase not only provides the target company with additional fundraising avenues and strengthens its overall financial strength but also brings industry experience, strategic resources, and a networking relationship that will promote the ongoing research and development work of the target company. Our company believes that the capital increase and the intended transactions under it align with the long-term strategic development goals of our group and are expected to enhance the financial strength of the target company.